Yogev Debbi Discusses the Future of Targeted Gene Delivery in Exclusive AI Pressroom Interview

In a recent feature by AI Pressroom, Mana.bio’s Co-founder and CEO, Yogev Debbi, delves into how Mana.bio is reshaping the future of genetic medicines through AI-powered lipid nanoparticle (LNP) delivery systems. The in-depth conversation explores the founding vision behind Mana.bio, the technological leap enabled by their proprietary AI platform, and how programmable delivery vehicles are opening new possibilities for precise and scalable gene therapy.

Yogev discusses the importance of cell-specific delivery, particularly to hard-to-target immune cells, and how Mana.bio’s innovations are accelerating preclinical programs and enabling novel therapeutic strategies. From platform partnerships to in vivo proof-of-concept data in non-human primates, the interview highlights the company's momentum and commitment to translating cutting-edge science into real-world therapies.

Read the full interview here.